Curium Group, PeptiDream and PDRadiopharma Announce Completion of Patient Dosing in Clinical Trial of 64Cu-PSMA-I&T for Prostate Cancer in Japan
Completion of patient dosing in the registrational Phase 2 clinical trial for 64Cu-PSMA-I&T – a PET radiopharmaceutical targeting prostate-specific membrane antigen (PSMA) expressed on prostate cancer cells Data analysis is now underway to support future regulatory submission in Japan BOSTON, June 11, 2026 (GLOBE NEWSWIRE) — Curium Group announced today that together with PeptiDream Inc. and […]
Original Source
Read the full article at Financialpost →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.